HBV dsRNA Composition for Rapid HBsAg and Viral Load Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis B virus (HBV) infection, such as interferon-based immunotherapies and HBV polymerase inhibitors, are ineffective in rapidly reducing HBsAg levels and do not restore immunological control in a large proportion of patients, leading to chronic infection and increased risk of liver disease and cancer.
Innovation Solution
Double-stranded ribonucleic acid (dsRNA) agents targeting HBV genes for RNA-induced silencing complex (RISC)-mediated cleavage, designed to inhibit HBV gene expression, replication, and antigen production, using modified nucleotides and ligands to enhance efficacy and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon-based immunotherapies or HBV polymerase inhibitors are used, then viral production is suppressed, but HBsAg levels are not rapidly reduced and immunological control is not restored in most patients
Solution Approach 1:
The patent uses chemically modified nucleotides (2'-O-methyl, 2'-fluoro, phosphorothioate linkages) to alter the physical and chemical parameters of the RNAi agent, enhancing its stability, cellular uptake, and RISC incorporation efficiency. This resolves the contradiction by creating an agent that maintains viral suppression while achieving rapid HBsAg reduction through improved molecular properties
Solution Approach 2:
The patent creates a composite RNAi agent combining multiple modified nucleotide types (2'-O-methyl, 2'-fluoro, phosphorothioate) within a single dsRNA molecule. This composite structure integrates the advantages of each modification type: enhanced stability from phosphorothioate linkages, improved cellular uptake from 2'-O-methyl groups, and optimized RISC loading from 2'-fluoro modifications, thereby achieving both sustained viral suppression and rapid HBsAg clearance
2Reliability
If current standard treatments are used, then some viral production suppression is achieved, but HBsAg clearance occurs only in a small percentage of patients with slow kinetics
Solution Approach 1:
The patent designs the dsRNA agent with pre-optimized structural features (modified nucleotides, specific duplex length, overhangs) that enable immediate and efficient incorporation into RISC upon cellular uptake. This preliminary optimization of the agent's molecular architecture ensures rapid target engagement and HBsAg clearance kinetics from the first dose, eliminating the slow progression seen with current therapies
Solution Approach 2:
By changing the chemical parameters of the RNAi agent through multiple nucleotide modifications, the patent enhances cellular uptake efficiency and endosomal escape, leading to faster intracellular delivery and more rapid HBsAg reduction. The phosphorothioate linkages provide nuclease resistance while 2'-O-methyl groups improve cellular permeability, collectively accelerating the therapeutic response
3Reliability
If HBV polymerase inhibitors are used long-term, then limited HBsAg reduction occurs, but treatment duration must be extended
Solution Approach 1:
The patent employs chemically modified nucleotides that confer resistance to nucleases and extend the half-life of the dsRNA agent within cells. The phosphorothioate linkages and 2'-O-methyl modifications create a stable complex that maintains sustained RISC incorporation and continuous HBsAg suppression, reducing the need for frequent dosing and long-term treatment extensions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA agents significantly inhibit HBV gene expression and antigen production, reducing viral load and antigen levels by up to 4 log10, thereby potentially achieving immunological control and preventing liver disease progression.
Implementation Method 1
double stranded ribonucleic acid (dsRNA) agents that affect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a Hepatitis B virus (HBV) gene
Data Source
Figure 1
Figure 2A~2B
Figure 3~4
AI summary
The present disclosure relates to double stranded RNA agents targeting the hepatitis B virus (HBV) genome, and methods of using such agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection or HBV-associated disorder, e.g., chronic hepatitis B infection.